Literature DB >> 25187092

Canagliflozin-Associated Acute Pancreatitis.

Rajanshu Verma1.   

Abstract

Canagliflozin is a new drug in class of sodium-glucose cotransporter 2 inhibitors used for treatment of type 2 diabetes mellitus. We describe a patient who developed moderately severe acute pancreatitis as an untoward consequence after being initiated on this drug. To the best of our knowledge, this is the first reported case of canagliflozin-associated acute pancreatitis in clinical literature.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25187092     DOI: 10.1097/MJT.0000000000000135

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  4 in total

1.  Probable Dapagliflozin-Associated Acute Pancreatitis.

Authors:  Ashlee D Barrett; Mason A Pitts; Elizabeth M Myers; Jeremy L Johnson
Journal:  Diabetes Spectr       Date:  2021-09-28

2.  Canagliflozin-induced pancreatitis: a rare side effect of a new drug.

Authors:  Mudit Chowdhary; Ahmad A Kabbani; Akansha Chhabra
Journal:  Ther Clin Risk Manag       Date:  2015-06-26       Impact factor: 2.423

Review 3.  Ever-increasing diversity of drug-induced pancreatitis.

Authors:  Simcha Weissman; Muhammad Aziz; Ryan B Perumpail; Tej I Mehta; Rutwik Patel; James H Tabibian
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

4.  Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.

Authors:  Peter Ueda; Henrik Svanström; Mads Melbye; Björn Eliasson; Ann-Marie Svensson; Stefan Franzén; Soffia Gudbjörnsdottir; Kristian Hveem; Christian Jonasson; Björn Pasternak
Journal:  BMJ       Date:  2018-11-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.